Company Overview and News


Add AFP
to your dashboard

Headline News

AFT Pharmaceuticals reports FY17 loss but sees return to profit on the horizon

2017-05-23 nzherald.co.nz
AFT Pharmaceuticals, which manufactures the Maxigesic painkiller, reported a full-year loss in the year to March 31 but expects to significantly narrow those deficits this year and return to profitability in the 2018/19 period.

AFT Pharmaceuticals raises $9.1m via redeemable share issue, announces SPP

2017-03-17 nzherald.co.nz
AFT Pharmaceuticals, which manufactures the Maxigesic painkiller, raised new funds through a redeemable share issue to fuel international growth and announced plans to raise more capital in a share purchase plan.

Market lower as reporting season fails to spark activity

2017-02-17 nzherald.co.nz
New Zealand shares fell, led lower by Sky Network Television and Spark New Zealand, while Auckland International Airport gained after its first-half profit rose 19 per cent.

AFT Pharmaceuticals expects sales to hit analyst forecast of $70 million

2017-02-16 nzherald.co.nz
AFT Pharmaceuticals, which manufactures the Maxigesic painkiller, expects annual sales to meet analysts' forecasts of about $70 million and has adjusted its loan covenant with shareholder Capital Royalty Group.

AFT Pharmaceuticals eyes higher sales after rescheduling of analgesics

2016-12-20 proactiveinvestors.com.au
The TGA has confirmed an interim decision that all medicines containing codeine be rescheduled to prescription-only medicines effective 1 February 2018. These products are being up-scheduled due to the risk of dependence and adverse events compared to safer analgesic products like Maxigesic. Maxigesic is a codeine-free analgesic that uses a patented combination of paracetamol and ibuprofen. AFT launched Maxigesic in Australia in 2014 and the brand is now becoming established with pharmacists and consumers.

Milford to close out new $150m private equity fund early

2016-12-20 nzherald.co.nz
Milford Asset Management will close out its recently launched private equity fund earlier than planned after finding more investor interest than expected.

NZ shares rise led by Tegel

2016-12-20 nzherald.co.nz
New Zealand shares rose as Tegel Group Holdings continued its rebound from last week's record low while Warehouse Group dropped after weaker earnings guidance.

AFT sees upside from restricted codeine sales

2016-12-20 nzherald.co.nz
New Zealand's AFT Pharmaceuticals expects to benefit from news that all medicines containing codeine will be prescription-only in Australia from February 1, 2018.

Index ends week on high note, rebounding from 5-day slide

2016-12-16 nzherald.co.nz
NZ shares rose, snapping five days of decline, with Tegel Group Holdings and A2 Milk Co recovering from being sold off earlier in the week, while Vista Group International and Infratil fell.

AFT to re-apply for heart medicine contract after shortages

2016-12-16 nzherald.co.nz
AFT Pharmaceuticals, the Auckland-based drug-maker, will have to re-apply to Pharmac for a heart medicine supply contract it won in July 2015 after suffering disrupted supply over the past year.

NZ shares rise led by Tower, Chorus, A2

2016-11-24 nzherald.co.nz
New Zealand shares rose, led by Tower, Chorus and A2 Milk, as the benchmark index's 14 percent slide from its early September highs drew some investors back to the market.

AFT H1 loss in line with expectations

2016-11-24 radionz.co.nz
The drug maker, AFT Pharmaceuticals, has reported an increased first half loss in line with expectations as it spent more on research and development and marketing.

AFT Pharmaceuticals posts $11 million first-half loss after boosting R&D spend

2016-11-23 nzherald.co.nz
AFT Pharmaceuticals, the Auckland-based drug-maker, widened its first-half loss to $11 million from $5.8m after ramping up research and development and launching over-the-counter products in Australia and Singapore.

Milford launches $150m private equity fund

2016-11-09 nzherald.co.nz
Investment manager Milford Asset Management is looking to raise up to $100 million to launch a new $150m private equity fund.

Tech sector cracks $1 billion in growth

2016-10-19 nzherald.co.nz
Tech companies' revenue increased by 12 per cent in the year to June, according to Technology Investment Network's TIN100 report released last night.

AFT Pharmaceuticals affirms it is on track to break even within two years

2016-08-05 nbr.co.nz
Drug developer AFT Pharmaceuticals [NZX: AFT] still expects to break even in the 2018 or 2019 financial year, although it cannot be sure exactly when, founder and managing director Harley Atkinson told shareholders at the company's first annual meeting since dual-listing on the NZX and ASX last December.

Tougher ASX rules to hit NZ companies

2016-07-21 newshub.co.nz
New admissions rules by the Australian Stock Exchange represent a new hurdle for the growing number of New Zealand companies listing across the Tasman.

Tougher admission rules to hit NZ companies with ASX listing plans

2016-07-20 nbr.co.nz
New admissions rules by the Australian Stock Exchange represent a new hurdle for the accelerating number of New Zealand companies listing across the Tasman.

MARKET CLOSE: NZ shares rise, Sky TV, Orion gain while Tower extends slide

2016-05-25 nbr.co.nz
New Zealand shares rose after Sky Network Television chief John Fellet said he'd resisted the temptation to acquire media assets and was await advice from Citibank that may include making a capital return. Orion Health Group also gained while Tower extended its decline.

Supplier problems cost AFT Pharmaceuticals $A2m

2016-05-25 nbr.co.nz
Credit card details are required to authenticate your account. You won't be charged until your trial has ended. Cancel anytime.

AFT Pharmaceuticals loss meets estimates

2016-05-25 news.theage.com.au
JavaScript disabled. Please enable JavaScript to use My News, My Clippings, My Comments and user settings.

AFT Pharmaceuticals loss meets estimates

2016-05-25 news.smh.com.au
JavaScript disabled. Please enable JavaScript to use My News, My Clippings, My Comments and user settings.

AFT posts loss that meets estimates in maiden result as Australian sales overtake NZ

2016-05-24 nbr.co.nz
AFT Pharmaceuticals [NZX: AFT], the Auckland-based drug developer, posted a $8.9 million operating loss for the year to March 31, its first result since listing on the NZX and ASX last December, and in line with analyst expectations.

AFT posts loss that meets estimates in maiden result

2016-05-24 nzherald.co.nz
AFT Pharmaceuticals, the Auckland-based drug developer, posted a $8.9 million operating loss for the year to March 31, its first result since listing on the NZX and ASX last December, and in line with analyst expectations. Total revenue rose 14 per cent to $64 million, in part reflecting ongoing fast sales growth in the Australian market of its flagship ibuprofen-paracetamol painkiller, Maxigesic. Australian sales rose 19 per cent to $31.